THE TOXICITY OF CHEMICALLY DEGLYCOSYLATED RICIN A-CHAIN IN MICE

被引:30
|
作者
SOLERRODRIGUEZ, AM
UHR, JW
RICHARDSON, J
VITETTA, ES
机构
[1] UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235
[2] UNIV TEXAS,DEPT PATHOL,DIV COMPARAT MED,DALLAS,TX 75235
[3] UNIV TEXAS,CTR CANC IMMUNOBIOL,DALLAS,TX 75235
来源
关键词
D O I
10.1016/0192-0561(92)90041-I
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Tumor-reactive antibodies coupled to ricin or its A-chain (immunotoxins) have been used in rodents and humans to treat a variety of neoplastic diseases. Side-effects of such treatment include hepatotoxicity, vascular leak syndrome, myalgia and low grade fever. At high doses, severe toxicities include liver damage, pulmonary edema, aphasia, rhabdomyolysis and kidney failure. There have been a limited number of toxicologic studies on uncoupled ricin or its A-chain and none on deglycosylated A-chain. Since the latter has been utilized in "second generation" immunotoxins, the current studies were carried out to evaluate the toxicities induced by deglycosylated ricin A-chain (dgA) in mice. The administration of dgA to normal BALB/c mice causes early (24 h) weight loss and late (10 day) accumulation of ascites. These effects could be partially altered by changing the route of injection of dgA from i.v. to i.p. Thus, i.p. administration caused weight loss but not ascites, whereas i.v. administration caused both. Weight loss was associated with reduced fluid intake by the treated mice, and was not associated with increased levels of serum TNF-alpha. SCID mice injected with the same dose of dgA as normal BALB/c mice developed ascites, but it was of lesser severity, suggesting that a functional immune system, differences in microbial flora, or strain differences may be involved in the development of ascites.
引用
收藏
页码:281 / 291
页数:11
相关论文
共 50 条
  • [41] Vinyldeoxyadenosine in a sarcin-ricin RNA loop and its binding to ricin toxin A-chain
    Roday, Setu
    Saen-oon, Suwipa
    Schramm, Vern L.
    BIOCHEMISTRY, 2007, 46 (21) : 6169 - 6182
  • [42] BREFELDIN-A ENHANCEMENT OF RICIN A-CHAIN IMMUNOTOXINS AND BLOCKADE OF INTACT RICIN, MODECCIN, AND ABRIN
    HUDSON, TH
    GRILLO, FG
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1991, 266 (28) : 18586 - 18592
  • [43] Recognition and interaction of small rings with the ricin A-chain binding site
    Yan, XJ
    Day, P
    Hollis, T
    Monzingo, AF
    Schelp, E
    Robertus, JD
    Milne, GWA
    Wang, SM
    PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1998, 31 (01): : 33 - 41
  • [44] In vitro selection of RNA molecules that inhibit the activity of ricin A-chain
    Hesselberth, JR
    Miller, D
    Robertus, J
    Ellington, AD
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (07) : 4937 - 4942
  • [45] Poly(amidoamine)-mediated intracytoplasmic delivery of ricin A-chain and gelonin
    Pattrick, NG
    Richardson, SCW
    Casolaro, M
    Ferruti, P
    Duncan, R
    JOURNAL OF CONTROLLED RELEASE, 2001, 77 (03) : 225 - 232
  • [46] ANTIBODY TO ONCOGENE PROTEIN PRODUCT AND ITS CONJUGATE WITH RICIN A-CHAIN
    刘辉
    隋文作
    刘连瑞
    Chinese Journal of Cancer Research, 1991, (04) : 51 - 54
  • [47] SENSITIVITY OF MALIGNANT LYMPHOID-CELLS TO RICIN A-CHAIN IMMUNOTOXINS
    LAURENT, G
    CASELLAS, P
    DEROCQ, JM
    PONCELET, P
    DUSSOSSOY, D
    JANSEN, F
    BRITISH JOURNAL OF CANCER, 1985, 52 (04) : 652 - 652
  • [48] Is there a clinical value for ricin A-chain immunotoxins in Hodgkins lymphoma.
    Schnell, R
    Staak, JO
    Vitetta, E
    Schindler, J
    Borchmann, P
    Barth, S
    Diehl, V
    Engert, A
    BLOOD, 2000, 96 (11) : 248B - 248B
  • [49] Transition-state analysis for depurination of DNA by ricin A-chain
    Chen, XY
    Berti, PJ
    Schramm, VL
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2000, 122 (28) : 6527 - 6534
  • [50] PREPARATION AND PROPERTIES OF A HYBRID TOXIN OF MODECCIN A-CHAIN AND RICIN B-CHAIN
    SUNDAN, A
    SANDVIG, K
    OLSNES, S
    BIOCHIMICA ET BIOPHYSICA ACTA, 1983, 761 (03) : 296 - 302